Pyxis Oncology, Inc. Increase Decrease In Operating Lease Liability
Pyxis Oncology, Inc. (PYXS) reported Increase Decrease In Operating Lease Liability of -$818.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- Pyxis Oncology, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$422.00K.
- Pyxis Oncology, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$396.00K.
- Pyxis Oncology, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$380.00K.
- Pyxis Oncology, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$370.00K.
- Pyxis Oncology, Inc. increase decrease in operating lease liability for fiscal 2025 was -$1.45M.
- Pyxis Oncology, Inc. increase decrease in operating lease liability for fiscal 2024 was -$1.23M, a 151.08% decline from fiscal 2023.
- Pyxis Oncology, Inc. increase decrease in operating lease liability for fiscal 2023 was $2.41M, a 43.41% decline from fiscal 2022.
- Pyxis Oncology, Inc. increase decrease in operating lease liability for fiscal 2022 was $4.26M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$422.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$818.00K 10-Q · filed 2026-08-13 | -$1.20M derived: sum of 3 quarters · filed 2026-08-13 | -$1.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$396.00K 10-Q · filed 2026-05-14 | -$776.00K derived: sum of 2 quarters · filed 2026-05-14 | -$1.15M derived: sum of 3 quarters · filed 2026-05-14 | -$1.51M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$750.00K derived: sum of 2 quarters · filed 2026-03-23 | -$1.11M derived: sum of 3 quarters · filed 2026-08-13 | -$1.45M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$370.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$732.00K derived: sum of 2 quarters · filed 2026-08-13 | -$1.07M 10-Q · filed 2025-11-03 | -$1.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$362.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$700.00K 10-Q · filed 2026-08-13 | -$1.02M derived: sum of 3 quarters · filed 2026-08-13 | -$1.34M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$338.00K 10-Q · filed 2026-05-14 | -$661.00K derived: sum of 2 quarters · filed 2026-05-14 | -$975.00K derived: sum of 3 quarters · filed 2026-05-14 | -$1.02M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$637.00K derived: sum of 2 quarters · filed 2026-03-23 | -$679.00K derived: sum of 3 quarters · filed 2026-03-23 | -$1.23M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$314.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$356.00K derived: sum of 2 quarters · filed 2025-11-03 | -$908.00K 10-Q · filed 2025-11-03 | -$1.20M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$594.00K 10-Q · filed 2025-08-14 | -$881.00K derived: sum of 3 quarters · filed 2025-08-14 | -$520.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$552.00K 10-Q · filed 2025-05-15 | -$839.00K derived: sum of 2 quarters · filed 2025-05-15 | -$478.00K derived: sum of 3 quarters · filed 2025-05-15 | $527.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $74.00K derived: sum of 2 quarters · filed 2025-03-18 | $1.08M derived: sum of 3 quarters · filed 2025-03-18 | $2.41M 10-K · filed 2025-03-18 |
| 2023-09-30 | $361.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.37M derived: sum of 2 quarters · filed 2024-11-12 | $2.70M 10-Q · filed 2024-11-12 | $6.39M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.34M 10-Q · filed 2024-08-14 | $6.03M derived: sum of 3 quarters · filed 2024-08-14 | $6.40M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.33M 10-Q · filed 2024-05-14 | $5.02M derived: sum of 2 quarters · filed 2024-05-14 | $5.39M derived: sum of 3 quarters · filed 2024-05-14 | $5.75M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $4.06M derived: sum of 2 quarters · filed 2024-03-21 | $4.42M derived: sum of 3 quarters · filed 2024-03-21 | $4.26M 10-K · filed 2024-03-21 |
| 2022-09-30 | $371.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $734.00K derived: sum of 2 quarters · filed 2023-11-07 | $569.00K 10-Q · filed 2023-11-07 | $409.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $363.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $198.00K 10-Q · filed 2023-08-11 | $38.00K derived: sum of 3 quarters · filed 2023-08-11 | -$118.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$165.00K 10-Q · filed 2023-05-11 | -$325.00K derived: sum of 2 quarters · filed 2023-05-11 | -$481.00K derived: sum of 3 quarters · filed 2023-05-11 | -$634.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$316.00K derived: sum of 2 quarters · filed 2023-03-22 | -$469.00K derived: sum of 3 quarters · filed 2023-03-22 | -$615.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | -$156.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$309.00K derived: sum of 2 quarters · filed 2022-11-01 | -$455.00K 10-Q · filed 2022-11-01 | -$598.00K derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | -$153.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$299.00K 10-Q · filed 2022-08-15 | -$442.00K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$146.00K 10-Q · filed 2022-05-13 | -$289.00K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | -$143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$421.00K 10-K · filed 2022-03-29 | ||
| 2020-09-30 | -$278.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |